Ontogeny of Drug-Metabolizing Enzymes.
Document Type
Article
Publication Date
2021
Identifier
DOI: 10.1007/978-1-0716-1554-6_18
Abstract
Almost 50% of prescription drugs lack age-appropriate dosing guidelines and therefore are used "off-label." Only ~10% drugs prescribed to neonates and infants have been studied for safety or efficacy. Immaturity of drug metabolism in children is often associated with drug toxicity. This chapter summarizes data on the ontogeny of major human metabolizing enzymes involved in oxidation, reduction, hydrolysis, and conjugation of drugs. The ontogeny data of individual drug-metabolizing enzymes are important for accurate prediction of drug pharmacokinetics and toxicity in children. This information is critical for designing clinical studies to appropriately test pharmacological hypotheses and develop safer pediatric drugs, and to replace the long-standing practice of body weight- or surface area-normalized drug dosing. The application of ontogeny data in physiologically based pharmacokinetic model and regulatory submission are discussed.
Journal Title
Methods in molecular biology (Clifton, N.J.)
Volume
2342
First Page
551
Last Page
593
Keywords
DME Ontogeny; Drug metabolism; Drug toxicity; PBPK modeling; Pediatric pharmacology
Recommended Citation
Thakur A, Parvez MM, Leeder JS, Prasad B. Ontogeny of Drug-Metabolizing Enzymes. Methods Mol Biol. 2021;2342:551-593. doi:10.1007/978-1-0716-1554-6_18
COinS
